As previously reported, Morgan Stanley upgraded DexCom (DXCM) to Overweight from Equal Weight with a price target of $75, up from $63, citing signs that the company is already turning the corner from a number of operational challenges while valuation remains at trough levels. The firm expects this turn to become apparent in the full results due in January or February, adding that it believes the G7 15-day rollout’s impact on margins in the year ahead is “underappreciated” and it expects the stock to re-rate as catalysts play out.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom upgraded to Overweight from Equal Weight at Morgan Stanley
- ServiceNow, Dexcom, Coinbase, Jumia, Keysight: Trending by Analysts
- OIG report looks positive for DexCom, says BofA
- DexCom initiated with an In Line at Evercore ISI
- DexCom announces FDA clearance of Smart Basal insulin dosing optimizer